Chemed 과거 순이익 실적
과거 기준 점검 2/6
Chemed의 수입은 연평균 -0.6%의 비율로 감소해 온 반면, Healthcare 산업은 수입이 연평균 4% 증가했습니다. 매출은 연평균 4.4%의 비율로 증가해 왔습니다. Chemed의 자기자본이익률은 30.6%이고 순이익률은 10.2%입니다.
핵심 정보
-0.55%
순이익 성장률
1.26%
주당순이익(EPS) 성장률
| Healthcare 산업 성장률 | 8.50% |
| 매출 성장률 | 4.42% |
| 자기자본이익률 | 30.64% |
| 순이익률 | 10.23% |
| 다음 순이익 업데이트 | 28 Jul 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • Jul 13
CHE: Share Repurchases And Steady Margins Will Support Measured Future Returns
Analysts have modestly raised their price target for Chemed to $474.0 from $446.5. This change reflects updated views on fair value, profit margins, and the P/E multiple they consider appropriate for the stock. What’s in the News for Chemed Chemed Corporation (NYSE: CHE) was removed from the Russell Small Cap Comp Growth Benchmark, according to index constituent change disclosures.
내러티브 업데이트 • Jun 29
CHE: Strong Q1 Results And Buybacks Support Balanced Future Return Potential
Analysts have revised their price target on Chemed to $500 from $580, reflecting updated assumptions for slightly higher discount rates, revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for Chemed Chemed reported Q1 revenue of $657.5 million, which was 1.6% higher year over year and 1.2% above analyst expectations, according to recent earnings coverage.내러티브 업데이트 • Jun 15
CHE: Share Repurchases And Stable Margins Will Support Balanced Future Returns
Analysts have kept their Chemed price target essentially unchanged at about $446.50, with only minimal tweaks to underlying assumptions such as revenue growth, profit margin, and future P/E to reflect updated modeling rather than a shift in overall outlook. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.내러티브 업데이트 • Jun 01
CHE: Ongoing Buybacks And Stable Margins Will Support Balanced Future Returns
Analysts have nudged their price target on Chemed higher to $446.50 from $443, reflecting updated assumptions around slightly stronger revenue growth, a modestly higher discount rate, stable profit margins, and a lower future P/E multiple. What's in the News Chemed reported that from January 1, 2026 to March 31, 2026, it repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.내러티브 업데이트 • Apr 27
CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns
Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).내러티브 업데이트 • Apr 10
CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns
Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.내러티브 업데이트 • Mar 27
CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns
Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).내러티브 업데이트 • Mar 10
CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns
Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).새로운 내러티브 • Feb 27
Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance
Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Feb 24
CHE: Stable Margins And Expanded Buybacks Will Support Future Upside
Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).내러티브 업데이트 • Feb 10
CHE: Stable Margins And Consistent Assumptions Will Support Future Upside
Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.내러티브 업데이트 • Jan 23
CHE: Share Buybacks And Margin Outlook Will Support Future Upside
Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.분석 기사 • Jan 16
Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...분석 기사 • Oct 31
Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results
It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...분석 기사 • Oct 24
Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$707 Chemed is estimated to be...Seeking Alpha • Oct 06
Chemed Corp: Genius Of The Model Lies In Its Corporate Strategy
Summary Chemed Corp's unconventional structure is masterfully managed with a disciplined focus on operational excellence and shareholder-friendly capital allocation. The company's primary competitive advantage is its brand, a powerful intangible asset cultivated over nearly a century of reliable service and effective marketing. Chemed has constructed a uniquely durable enterprise built to create shareholder value for the long term. Read the full article on Seeking Alpha내러티브 업데이트 • Sep 03
New Florida CON Sites Will Advance Home-Based And Hospice Care
Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.매출 및 비용 세부 내역
매출 및 비용 세부 내역
Chemed가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 2,541 | 260 | 423 | 0 |
| 31 Dec 25 | 2,530 | 265 | 414 | 0 |
| 30 Sep 25 | 2,531 | 279 | 416 | 0 |
| 30 Jun 25 | 2,512 | 290 | 407 | 0 |
| 31 Mar 25 | 2,489 | 309 | 414 | 0 |
| 31 Dec 24 | 2,431 | 302 | 419 | 0 |
| 30 Sep 24 | 2,377 | 302 | 415 | 0 |
| 30 Jun 24 | 2,336 | 301 | 418 | 0 |
| 31 Mar 24 | 2,293 | 283 | 406 | 0 |
| 31 Dec 23 | 2,264 | 273 | 395 | 0 |
| 30 Sep 23 | 2,225 | 245 | 392 | 0 |
| 30 Jun 23 | 2,187 | 226 | 376 | 0 |
| 31 Mar 23 | 2,165 | 240 | 369 | 0 |
| 31 Dec 22 | 2,135 | 250 | 359 | 0 |
| 30 Sep 22 | 2,129 | 262 | 354 | 0 |
| 30 Jun 22 | 2,141 | 277 | 359 | 0 |
| 31 Mar 22 | 2,142 | 267 | 365 | 0 |
| 31 Dec 21 | 2,139 | 269 | 367 | 0 |
| 30 Sep 21 | 2,132 | 308 | 361 | 0 |
| 30 Jun 21 | 2,121 | 303 | 361 | 0 |
| 31 Mar 21 | 2,091 | 329 | 351 | 0 |
| 31 Dec 20 | 2,080 | 319 | 330 | 0 |
| 30 Sep 20 | 2,069 | 271 | 322 | 0 |
| 30 Jun 20 | 2,021 | 263 | 311 | 0 |
| 31 Mar 20 | 1,992 | 231 | 298 | 0 |
| 31 Dec 19 | 1,939 | 220 | 306 | 0 |
| 30 Sep 19 | 1,874 | 209 | 289 | 0 |
| 30 Jun 19 | 1,837 | 201 | 279 | 0 |
| 31 Mar 19 | 1,806 | 205 | 276 | 0 |
| 31 Dec 18 | 1,783 | 206 | 271 | 0 |
| 30 Sep 18 | 1,753 | 206 | 276 | 0 |
| 30 Jun 18 | 1,727 | 190 | 275 | 0 |
| 31 Mar 18 | 1,700 | 113 | 271 | 0 |
| 31 Dec 17 | 1,667 | 98 | 271 | 0 |
| 30 Sep 17 | 1,642 | 76 | 261 | 0 |
| 30 Jun 17 | 1,617 | 67 | 254 | 0 |
| 31 Mar 17 | 1,592 | 114 | 249 | 0 |
| 31 Dec 16 | 1,577 | 109 | 238 | 0 |
| 30 Sep 16 | 1,572 | 106 | 240 | 0 |
| 30 Jun 16 | 1,566 | 108 | 234 | 0 |
| 31 Mar 16 | 1,557 | 111 | 233 | 0 |
| 31 Dec 15 | 1,543 | 110 | 233 | 0 |
| 30 Sep 15 | 1,524 | 110 | 229 | 0 |
양질의 수익: CHE는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: CHE의 현재 순 이익률 (10.2%)은 지난해 (12.4%)보다 낮습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: CHE의 수익은 지난 5년 동안 연평균 0.6% 감소했습니다.
성장 가속화: CHE은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.
수익 대 산업: CHE은 지난 1년 동안 수익이 감소(-15.9%)하여 Healthcare 업계 평균(15.3%)과 비교하기 어렵습니다.
자기자본이익률
높은 ROE: CHE의 자본 수익률(30.6%)은 높음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/17 01:04 |
| 종가 | 2026/07/17 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Chemed Corporation는 10명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Adam Feinstein | Barclays |
| Joanna Sylvia Gajuk | BofA Global Research |
| Peter Martin | Citizens JMP Securities, LLC |